Device Trial Radar · NCT04770285
Trial to Evaluate the Effectiveness of a Digital Therapeutics in Adults Diagnosed With Major Depressive Disorder
Last checked: Nov 20, 2026Latest source record: Oct 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
386
Actual
Start
Feb 25, 2021
Primary completion
Oct 26, 2022
Study completion Oct 26, 2022
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Click Therapeutics, Inc.
- First posted
- Feb 25, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study compares the effectiveness of 2 digital therapeutics in adult participants diagnosed with major depressive disorder (MDD) who are on antidepressant therapy (ADT) monotherapy for the treatment of depression.
Conditions
- Major Depressive Disorder
Interventions
CT-152 - Digital TherapeuticDevice
CT-152 mobile app was used by the participants as per the schedule specified in the respective arm.
ShamDevice
Sham mobile app was used by the participants as per the schedule specified in the respective arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 6 in the MADRS Total ScoreTime frame: Baseline (Day 1) to Week 6
Locations
1 site in 1 country. Site status is shown where the registry gives one.
For additional information regarding sites, contact 844-687-8522
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.